Healthy Inc > Blog > malaria tender supply
Posted on:

What is the use of artesunate and amodiaquine tablets?

In the pharmaceutical industry, the combination of Artesunate and Amodiaquine (AS+AQ) is a cornerstone of Artemisinin-based Combination Therapy (ACT). As a pharmacist, I view this fixed-dose combination (FDC) as a vital public health tool, specifically engineered to combat Plasmodium falciparum malaria by providing a “one-two punch” that eliminates parasites at different stages of their life cycle.

Primary Clinical Uses

  • Treatment of Uncomplicated Malaria: Indicated as a first-line therapy for acute, uncomplicated malaria infections, especially in regions with high chloroquine resistance.

  • Pediatric and Adult Populations: Available in specific weight-based strengths (e.g., 25/67.5 mg, 50/135 mg, and 100/270 mg) to ensure precise dosing and reduce the risk of sub-therapeutic treatment.

  • Rapid Parasite Clearance: Used to achieve high cure rates (typically >95%) and to prevent the progression of the disease into severe, life-threatening malaria.

Mechanism of Action

This FDC utilizes two distinct chemical classes to ensure maximum parasiticidal effect:

Artesunate (Artemisinin Derivative): It acts rapidly by reacting with the iron in the parasite’s heme to generate reactive free radicals. These radicals cause widespread damage to the parasite’s cell membranes and essential proteins, resulting in a rapid “knockdown” of the parasite load.

Amodiaquine (4-Aminoquinoline): It acts as a long-acting blood schizontocide. It interferes with the parasite’s ability to detoxify heme (converting it into non-toxic hemozoin). The resulting accumulation of toxic free heme leads to the death of any parasites that survived the initial Artesunate burst.

The Manufacturer’s Perspective: Formulation & Export

From a manufacturing and global trade standpoint, AS+AQ is a technically sensitive product that demands high-tier quality control:

  • Bilayer Tablet Technology: Because Artesunate is highly sensitive to moisture and can interact with the Amodiaquine salt, we often utilize bilayer compression. This physical separation within a single tablet enhances the stability and shelf-life of the product.

  • Hygroscopic Protection: Artesunate is moisture-labile. As a WHO-GMP manufacturer, we utilize Alu-Alu blister packaging to provide a superior moisture barrier, ensuring the tablets remain stable in Zone IVb (hot and humid) climates.

  • Global Health Compliance: This combination is a staple for international health tenders (e.g., Global Fund, USAID). Our Mumbai-based facility is optimized for high-capacity production with full CTD/eCTD Dossier support for rapid international registration.

  • Safety Monitoring: We adhere to strict API standards to minimize the risk of rare adverse effects like neutropenia or hepatotoxicity, ensuring the product is as safe as it is effective.

Artesunate Amodiaquine Tablets

Posted on:

What is the use of artesunate sulfadoxine pyrimethamine tablet?

In the pharmaceutical industry, the combination of Artesunate and Sulfadoxine-Pyrimethamine (AS+SP) is a powerful Artemisinin-based Combination Therapy (ACT). As a pharmacist, I characterize this fixed-dose combination (FDC) as a strategic multi-target treatment designed to clear parasites rapidly while providing a long-acting “chemical umbrella” to prevent the recurrence of infection.

Primary Clinical Uses

  • Treatment of Uncomplicated Malaria: Indicated for the treatment of acute, uncomplicated malaria infections caused by Plasmodium falciparum in areas where the parasite remains sensitive to the SP component.

  • Rapid Parasite Clearance: The Artesunate component ensures that the parasite load in the blood is reduced within hours, preventing the onset of severe malaria.

  • Prevention of Recrudescence: The long-acting Sulfadoxine and Pyrimethamine components remain in the bloodstream for weeks to kill any residual parasites.

  • Intermittent Preventive Treatment (IPT): In specific high-risk regions, this combination is sometimes utilized in pregnancy (IPTp) or for infants (IPTi) to reduce the burden of malaria.

Mechanism of Action

This combination employs a dual-mechanism approach to ensure parasitic death:

Artesunate (Fast-Acting): Generates reactive free radicals that damage the parasite’s proteins and membranes by reacting with the iron in the parasite’s food vacuole. It targets the asexual erythrocytic stages.

Sulfadoxine & Pyrimethamine (Long-Acting): These act as sequential inhibitors of folic acid synthesis. Sulfadoxine inhibits the enzyme dihydropteroate synthase, while Pyrimethamine inhibits dihydrofolate reductase. Since parasites must synthesize their own folates for DNA production, this blockade effectively halts their replication.

The Manufacturer’s Perspective: Formulation & Export

From a manufacturing and global trade standpoint, AS+SP is a specialized product requiring high-tier regulatory compliance:

  • Stability Management: Artesunate is highly sensitive to moisture and heat. As a WHO-GMP manufacturer, we utilize Alu-Alu blister packaging and low-humidity manufacturing zones to protect the integrity of the Artesunate API during storage and transit.

  • Fixed-Dose Precision: We ensure that the ratio of Sulfadoxine to Pyrimethamine is precisely 20:1 (typically 500 mg/25 mg) to maintain the synergistic effect while minimizing potential side effects.

  • Global Export Niche: This combination is a staple for B2B distributors and government health tenders in sub-Saharan Africa and Southeast Asia. Our Mumbai hub is optimized for high-capacity production to meet international public health demands.

  • Regulatory Dossiers: We provide comprehensive CTD/eCTD documentation and stability data for Zone IVb to facilitate smooth registration in malaria-endemic international markets.

Artesunate Sulphadoxine Pyrimethamine Tablets

Posted on:

What is the use of artesunate sulfadoxine pyrimethamine tablet?

In the pharmaceutical industry, the combination of Artesunate and Sulfadoxine-Pyrimethamine (AS+SP) is a powerful Artemisinin-based Combination Therapy (ACT). As a pharmacist, I characterize this fixed-dose combination (FDC) as a strategic multi-target treatment designed to clear parasites rapidly while providing a long-acting “chemical umbrella” to prevent the recurrence of infection.

Primary Clinical Uses

  • Treatment of Uncomplicated Malaria: Indicated for the treatment of acute, uncomplicated malaria infections caused by Plasmodium falciparum in areas where the parasite remains sensitive to the SP component.

  • Rapid Parasite Clearance: The Artesunate component ensures that the parasite load in the blood is reduced within hours, preventing the onset of severe malaria.

  • Prevention of Recrudescence: The long-acting Sulfadoxine and Pyrimethamine components remain in the bloodstream for weeks to kill any residual parasites.

  • Intermittent Preventive Treatment (IPT): In specific high-risk regions, this combination is sometimes utilized in pregnancy (IPTp) or for infants (IPTi) to reduce the burden of malaria.

  • Mechanism of Action

This combination employs a dual-mechanism approach to ensure parasitic death:

Artesunate (Fast-Acting): Generates reactive free radicals that damage the parasite’s proteins and membranes by reacting with the iron in the parasite’s food vacuole. It targets the asexual erythrocytic stages.

Sulfadoxine & Pyrimethamine (Long-Acting): These act as sequential inhibitors of folic acid synthesis. Sulfadoxine inhibits the enzyme dihydropteroate synthase, while Pyrimethamine inhibits dihydrofolate reductase. Since parasites must synthesize their own folates for DNA production, this blockade effectively halts their replication.

The Manufacturer’s Perspective: Formulation & Export

From a manufacturing and global trade standpoint, AS+SP is a specialized product requiring high-tier regulatory compliance:

  • Stability Management: Artesunate is highly sensitive to moisture and heat. As a WHO-GMP manufacturer, we utilize Alu-Alu blister packaging and low-humidity manufacturing zones to protect the integrity of the Artesunate API during storage and transit.

  • Fixed-Dose Precision: We ensure that the ratio of Sulfadoxine to Pyrimethamine is precisely 20:1 (typically 500mg/25mg) to maintain the synergistic effect while minimizing potential side effects.

  • Global Export Niche: This combination is a staple for B2B distributors and government health tenders in sub-Saharan Africa and Southeast Asia. Our Mumbai hub is optimized for high-capacity production to meet international public health demands.

  • Regulatory Dossiers: We provide comprehensive CTD/eCTD documentation and stability data for Zone IVb to facilitate smooth registration in malaria-endemic international markets.

 

Posted on:

What is the use of Artemether and Lumefantrine tablets?

In the pharmaceutical industry, Artemether and Lumefantrine tablets (available in 20 mg/120 mg or 80 mg/480 mg strengths) represent the gold standard in Artemisinin-based Combination Therapy (ACT). As a pharmacist, I view this specific fixed-dose combination (FDC) as the most critical frontline defense against multi-drug resistant malaria.

Primary Clinical Uses

  • Uncomplicated Malaria: Indicated for the treatment of acute, uncomplicated malaria infections caused by Plasmodium falciparum, including infections acquired in chloroquine-resistant areas.

  • Pediatric and Adult Populations: Used widely across all age groups (standardized by weight) to ensure rapid clearance of parasites from the blood.

  • Stand-by Emergency Treatment: Often carried by travelers to malaria-endemic regions as a self-administered emergency treatment when medical facilities are unavailable.

Mechanism of Action

This combination provides a dual-phase attack on the malaria parasite:

Artemether: A semi-synthetic derivative of artemisinin. It acts rapidly to provide a fast “knockdown” of the parasite load by generating reactive free radicals that disrupt the parasite’s membrane and proteins.

Lumefantrine: A long-acting fluorene derivative. It acts more slowly but stays in the system longer to clear any residual parasites that survived the initial Artemether burst, preventing recrudescence (relapse).

The Manufacturer’s Perspective: Formulation & Export

From a manufacturing and global trade standpoint, Artemether-Lumefantrine is a high-precision product requiring stringent quality controls:

  • Fixed-Dose Combination (FDC) Stability: Artemether is a relatively unstable molecule sensitive to heat and moisture. As a WHO-GMP manufacturer, we utilize specialized granulation processes and Alu-Alu blister packaging to ensure stability, particularly for export to the high-heat environments of Africa and Southeast Asia.

  • Bioavailability: Lumefantrine has highly variable absorption. Our formulation includes specific excipients to ensure consistent absorption, especially when taken with fatty foods, which is a critical clinical requirement.

  • Global Health Tenders: This is a high-volume item for international NGOs, UNICEF, and the Global Fund. Our Mumbai-based facility is optimized to meet the massive demand for these tenders with full CTD/eCTD Dossier support.

  • Pediatric Dispersible Tablets: We also focus on dispersible formulations with pleasant flavoring to ensure easy administration and compliance in children, which is vital for reducing child mortality.

Artemether & Lumefantrine Tablets

Posted on:

What is the use of Artemether and Lumefantrine tablets?

In the pharmaceutical industry, Artemether and Lumefantrine tablets (available in 20 mg/120 mg or 80 mg/480 mg strengths) represent the gold standard in Artemisinin-based Combination Therapy (ACT). As a pharmacist, I view this specific fixed-dose combination (FDC) as the most critical frontline defense against multi-drug resistant malaria.

Primary Clinical Uses

  • Uncomplicated Malaria: Indicated for the treatment of acute, uncomplicated malaria infections caused by Plasmodium falciparum, including infections acquired in chloroquine-resistant areas.

  • Pediatric and Adult Populations: Used widely across all age groups (standardized by weight) to ensure rapid clearance of parasites from the blood.

  • Stand-by Emergency Treatment: Often carried by travelers to malaria-endemic regions as a self-administered emergency treatment when medical facilities are unavailable.

Mechanism of Action

This combination provides a dual-phase attack on the malaria parasite:

Artemether: A semi-synthetic derivative of artemisinin. It acts rapidly to provide a fast “knockdown” of the parasite load by generating reactive free radicals that disrupt the parasite’s membrane and proteins.

Lumefantrine: A long-acting fluorene derivative. It acts more slowly but stays in the system longer to clear any residual parasites that survived the initial Artemether burst, preventing recrudescence (relapse).

The Manufacturer’s Perspective: Formulation & Export

From a manufacturing and global trade standpoint, Artemether-Lumefantrine is a high-precision product requiring stringent quality controls:

  • Fixed-Dose Combination (FDC) Stability: Artemether is a relatively unstable molecule sensitive to heat and moisture. As a WHO-GMP manufacturer, we utilize specialized granulation processes and Alu-Alu blister packaging to ensure stability, particularly for export to the high-heat environments of Africa and Southeast Asia.

  • Bioavailability: Lumefantrine has highly variable absorption. Our formulation includes specific excipients to ensure consistent absorption, especially when taken with fatty foods, which is a critical clinical requirement.

  • Global Health Tenders: This is a high-volume item for international NGOs, UNICEF, and the Global Fund. Our Mumbai-based facility is optimized to meet the massive demand for these tenders with full CTD/eCTD Dossier support.

  • Pediatric Dispersible Tablets: We also focus on dispersible formulations with pleasant flavoring to ensure easy administration and compliance in children, which is vital for reducing child mortality.

Artemether & Lumefantrine Tablets

Posted on:

What is the use of Artemether and Lumefantrine tablets?

In the pharmaceutical industry, Artemether and Lumefantrine tablets (commonly in 20 mg/120 mg or 80 mg/480 mg strengths) represent the gold standard in Artemisinin-based Combination Therapy (ACT). As a pharmacist, I view this specific fixed-dose combination (FDC) as the most critical frontline defense against multi-drug resistant malaria.

Primary Clinical Uses

  • Uncomplicated Malaria: Indicated for the treatment of acute, uncomplicated malaria infections caused by Plasmodium falciparum, including infections acquired in chloroquine-resistant areas.

  • Pediatric and Adult Populations: Used widely across all age groups (standardized by weight) to ensure rapid clearance of parasites from the blood.

  • Stand-by Emergency Treatment: Often carried by travelers to malaria-endemic regions as a self-administered emergency treatment when medical facilities are unavailable.

Mechanism of Action

This combination provides a dual-phase attack on the malaria parasite:

Artemether: A semi-synthetic derivative of artemisinin. It acts rapidly to provide a fast “knockdown” of the parasite load by generating reactive free radicals that disrupt the parasite’s membrane and proteins.

Lumefantrine: A long-acting fluorene derivative. It acts more slowly but stays in the system longer to clear any residual parasites that survived the initial Artemether burst, preventing recrudescence (relapse).

The Manufacturer’s Perspective: Formulation & Export

From a manufacturing and global trade standpoint, Artemether-Lumefantrine is a high-precision product requiring stringent quality controls:

  • Fixed-Dose Combination (FDC) Stability: Artemether is a relatively unstable molecule sensitive to heat and moisture. As a WHO-GMP manufacturer, we utilize specialized granulation processes and Alu-Alu blister packaging to ensure stability, particularly for export to the high-heat environments of Africa and Southeast Asia.

  • Bioavailability: Lumefantrine has highly variable absorption. Our formulation includes specific excipients to ensure consistent absorption, especially when taken with fatty foods, which is a critical clinical requirement.

  • Global Health Tenders: This is a high-volume item for international NGOs, UNICEF, and the Global Fund. Our Mumbai-based facility is optimized to meet the massive demand for these tenders with full CTD/eCTD Dossier support.

  • Pediatric Dispersible Tablets: We also focus on dispersible formulations with pleasant flavoring to ensure easy administration and compliance in children, which is vital for reducing child mortality.

Artemether & Lumefantrine Tablets

Add to cart